NEW YORK, May 24, 2017 /PRNewswire/ -- Xarelto patients who suffered internal bleeding and other life-threatening complications allegedly related to use of the medication continue to file lawsuits in courts throughout the U.S. According to a May 3rd filing with the U.S. Securities and Exchange Commission, Johnson & Johnson and Bayer AG have been named defendants in at least 18,900 Xarelto lawsuits, most of which are pending in a federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana. Xarelto litigations have also been established in state courts in Pennsylvania, Delaware, California and Missouri, while class action lawsuits have been filed in Canada.
"Our Firm is representing a number of Xarelto lawsuit plaintiffs, and we continue to receive inquiries from others who were allegedly harmed by this blood thinner. We are not surprised that the litigation surrounding this medication continues to grow," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm continues to evaluate potential Xarelto lawsuits on behalf of individuals who may have been harmed by this blood-thinning medication.
Xarelto is an oral anticoagulant jointly marketed by Bayer and Johnson & Johnson. The blood thinner was approved by the U.S. Food & Drug Administration (FDA) in 2011, and is currently indicated for the prevention of strokes in atrial fibrillation patients; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee implant surgery.
Xarelto plaintiffs allege that Bayer and Johnson & Johnson failed to provide adequate warnings regarding uncontrollable bleeding that may occur with its use, and wrongly promoted the blood thinner as a superior alternative to warfarin. Among other things, plaintiffs note that bleeding associated with warfarin can be reversed via the administration of vitamin K. However, there is currently no approved antidote to stop Xarelto bleeding events.
The multidistrict litigation underway in the Eastern District of Louisiana houses at least 16,670 Xarelto lawsuits. The proceeding is scheduled to convene its second bellwether trial on May 30th in New Orleans. Verdicts in these trials may provide insight into how juries could rule in similar Xarelto claims. Johnson & Johnson and Bayer prevailed in the first Xarelto trial, which concluded earlier this month. (In Re: Xarelto Products Liability Litigation, No. 2592).
Xarelto patients who allegedly experienced bleeding-related complications may be entitled to compensation for their medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xarelto-lawsuit-filings-exceed-18000-as-second-bellwether-trial-set-to-get-underway-bernstein-liebhard-llp-reports-300463338.html
SOURCE Bernstein Liebhard LLP